# Recursion (RXRX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/RXRX
## Company Profile
- Ticker: RXRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Biologics
## Stock Data
- Close: 3.17 USD
- Market cap: 1916051534.78 USD
- Last updated: 2026-08-05
## Business Overview
### AI-Native Drug Discovery
Recursion is a clinical-stage TechBio company using an integrated discovery and development platform to generate medicines across oncology, rare disease, neuroscience and immunology. The Recursion OS combines proprietary multimodal biological and chemical data, purpose-built AI models and experimental validation.
### REC-1245
REC-1245 is a potential first-in-class RBM39 degrader being evaluated in the Phase 1/2 DAHLIA study for solid tumors. Early dose-escalation results showed predictable pharmacokinetics and no dose-limiting toxicities, supporting continued evaluation of monotherapy expansion doses.
### REC-4881
REC-4881 is a MEK1/2 inhibitor in Phase 2 development for familial adenomatous polyposis. Recursion has observed efficacy signals and has begun discussions with the FDA regarding a potential registrational development path.
### REC-4539
REC-4539 is a selective, brain-penetrant and reversible LSD1 inhibitor in Phase 1 development for solid tumors and acute myeloid leukemia. Its reversible mechanism is intended to reduce the platelet toxicity associated with sustained LSD1 inhibition.
### Platform-Derived Portfolio
The company advances both wholly owned and partnered candidates, using clinical programs as validation points for the speed and translational potential of its AI-enabled platform. REC-1245, for example, moved from biological discovery to a development candidate in approximately 18 months.
## Why The Stock Is Moving

Following the latest company update, “Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program”, RXRX closed down 4.23% at $3.17 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Regulatory update on the potential registrational path for REC-4881 expected in the second half of 2026.
- Additional Phase 1 dose-escalation data for REC-1245 expected in the second half of 2026.
- Additional Phase 1b/2 clinical data for REC-4881 expected in the first half of 2027.

## Recent News
- 2026-08-05 10:30 EST — [Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program](https://biopharmsignal.com/news/RXRX/recursion-reports-second-quarter-financial-results-genentech-options-first-neuro-2ed0e822) — Source: Recursion
- 2026-07-29 12:30 EST — [Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th](https://biopharmsignal.com/news/RXRX/recursion-to-report-second-quarter-2026-business-updates-and-financial-results-o-9a849d6b) — Source: Recursion
- 2026-06-02 12:00 EST — [Recursion to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-f4e26896) — Source: Recursion
- 2026-05-29 20:30 EST — [Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules](https://biopharmsignal.com/news/RXRX/recursion-reports-grant-of-inducement-awards-as-permitted-by-the-nasdaq-listing--92e9e803) — Source: Recursion
- 2026-05-06 10:30 EST — [Recursion Reports First Quarter Financial Results and Provides Business Update](https://biopharmsignal.com/news/RXRX/recursion-reports-first-quarter-financial-results-and-provides-business-update-5395800d) — Source: Recursion